Gilead Sciences

Gilead to Acquire MYR for ~$1.4B

  • by

Shots: Gilead to acquire MYR for ~$1.4B in the all-cash transaction along with ~$364.73M as a milestone upon the US FDA’s approval of Hepcludex (bulevirtide) The acquisition will provide Gilead with Hepcludex which has received EMA’s conditional approval for chronic HDV infection in adults with… Read More »Gilead to Acquire MYR for ~$1.4B

Kronos Bio raises $155M in private financing to advance lead leukemia drug into registration study next year

  • by

The company has raised $148 million so far and plans to raise the remaining $7 million by next month. Its lead candidate is entospletinib, a SYK inhibitor acquired as part of a deal with Gilead Sciences last month, under development for patients with biomarker-defined acute… Read More »Kronos Bio raises $155M in private financing to advance lead leukemia drug into registration study next year